Low numbers of tryptase+ and chymase+ mast cells associated with reduced survival and advanced tumor stage in melanoma

Melanoma Research

Volumn 25, Issue 6, 2015, Pages 479-485

  Siiskonen, Hanna ^a   Poukka, Mari ^a   Bykachev, Andrey ^a   Tyynelä Korhonen, Kristiina ^a   Sironen, Reijo ^a   Pasonen Seppänen, Sanna ^a   Harvima, Ilkka T ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Chymase; Cutaneous; Mast cell; Melanoma; Tryptase

Indexed keywords

CHYMASE; PARAFFIN; TRYPTASE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BENIGN TUMOR; CANCER STAGING; CANCER SURVIVAL; CELL SURVIVAL; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; DYSPLASTIC NEVUS; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU MELANOMA; INVASIVE MELANOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MAST CELL; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECRETORY GRANULE; SKINFOLD THICKNESS; BIOSYNTHESIS; ENZYMOLOGY; IMMUNOLOGY; KAPLAN MEIER METHOD; MELANOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; SKIN TUMOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHYMASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MAST CELLS; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TRYPTASES; YOUNG ADULT;

EID: 84946225457     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000192     Document Type: Article

References (47)

1. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27:3-9.
2. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46:270-2 83.
3. Tan JD, Butow PN, Boyle FM, Saw RP, O'Reilly AJ. A qualitative assessment of psychosocial impact, coping and adjustment in high-risk melanoma patients and caregivers. Melanoma Res 2014; 24:252-260.
4. Hill VK, Gartner JJ, Samuels Y, Goldstein AM. The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet 2013; 14:257-279.
5. Dahlke E, Mur ray CA, Kitchen J, Chan AW. Systematic review of melanoma incidence and prognosis in solid organ transplant recipients. Transplant Res 2014; 3:10.
6. Harvima IT, Nilsson G, Suttle MM, Naukkarinen A. Is there a role for mast cells in psoriasis? Arch Dermatol Res 2008; 300:461-478.
7. Harvima IT, Levi-Schaffer F, Draber P, Friedman S, Polakovicova I, Gibbs BF, et al. Mol ecular targets on mast cells and basophils for novel therapies. J Allergy Clin Immunol 2014; 134:530-544.
8. Tay SS, Roediger B, Tong PL, Tikoo S, Weninger W. The skin-resident immune network. Curr Dermatol Rep 2014; 3:13-22.
9. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST. Mast cells and cutaneous malignancies. Mod Pathol 2006; 19:149-159.
10. Marichal T, Tsai M, Galli SJ. Mast cells: potential positive and negative roles in tumor biology. Cancer Immunol Res 2013; 1:269-279.
11. Tan SY, Fan Y, Luo HS, Shen ZX, Guo Y, Zhao LJ. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol 2005; 11:1210-1214.
12. Ribatti D. Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis Immunol Lett 2013 152 83-88.
13. Biswas A, Richards JE, Massaro J, Mahalingam M. Mast cells in cutaneous tumors: innocent bystander or maestro conductor? Int J Dermatol 2014; 53:806-811.
14. Beer TW, Ng LB, Murray K. Mast cells have prognostic value in Merkel cell carcinoma. Am J Dermatopathol 2008; 30:27-30.
15. Rabenhorst A, Schlaak M, Heukamp LC, Förster A, Theurich S, von Bergwelt-Baildon M, et al. Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood 2012; 120:2042-2054.
16. Duncan LM, Richards LA, Mihm MC Jr. Increased mast cell density in invasive melanoma. J Cutan Pathol 1998; 25:11-15.
17. Tó th-Jakatics R, Jimi S, Takebayashi S, Kawamoto N. Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. Hum Pathol 2000; 31:955-960.
18. Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, Sirigu P. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 2003; 33:420-425.
19. Diaconu NC, Rummukainen J, Naukkarinen A, MättöM, Harvima RJ, Pelkonen J, Harvima IT. Mast cell chymase is present in uterine cervical carcinoma and it detaches viable and growing cervical squamous carcinoma c ells from substratum in vitro. Arch Dermatol Res 2011; 303:499-512.
20. Harvima IT, Naukkarinen A, Paukkonen K, Harvima RJ, Aalto ML, Schwartz LB, Horsmanheimo M. Mast cell tryptase a nd chymase in developing and mature psoriatic lesions. Arch Dermatol Res 1993; 285:184-192.
21. Simionescu C, Margaritescu C, Stepan A, Pirici D, Ciurea R, Cernea N. Tumor angiogenesis, ma crophages and mast cell microdensities in endometrioid endometrial carcinoma. Oncol Lett 2013; 6:415-420.
22. Tiainen S, Tumelius R, Rilla K, Hämäläinen K, Tammi M, Tammi R, et al. Hi gh numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer. Histopathology 2015; 66:873-883.
23. Weber A, Knop J, Maurer M. Pattern analysis of human cutaneous mast cell populations by total body surface mapping. Br J Dermatol 2003; 148:224-228.
24. Diaconu NC, Kaminska R, Naukkarinen A, Harvima RJ, Harvima IT. The increase in tryptase-And chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma. J Eur Acad Dermatol Venereol 2007; 21:908-915.
25. Salgado CM, Silver RB, Bauer BS, Basu D, Schmitt L, Khakoo Y, Reyes-Múgica M. Skin of patients with large/giant congenital melanocytic nevi shows increased mast cells. Pediatr Dev Pathol 2014; 17:198-203.
26. Kaukinen A, Fitzgibbon A, Oikarinen A, Hinkkanen L, Viinikanoja M, Harvima IT. Increased numbers of tryptase-positive mast cells in the healthy and sun-protected skin of tobacco smokers. Dermat ology 2014; 229:353-358.
27. Song F, Qureshi AA, Gao X, Li T, Han J. Smoking and risk of skin cancer: a prospective analysis and a meta-Analysis. Int J Epidemiol 2012; 41:1694-1705.
28. Ribatti D, Vacca A, Ria R, Marzullo A, Nico B, Filotico R, et al. Neovascularisation, expression of fibroblast growth factor-2, an d mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur J Cancer 2003; 39:666-674.
29. Siebenhaar F, Metz M, Maurer M. Mast cells pro tect from skin tumor development and limit tumor growth during cutaneous de novo carcinogenesis in a kit-dependent mouse model. Exp Dermatol 2014; 23:159-164.
30. Oldford SA, Marshall JS. Mast cells as targets for immunotherapy of solid tumors. Mol Immunol 2015; 63:113-124.
31. Samoszuk M, Kanakubo E, Chan JK. Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts. BMC Cancer 2005; 5:121.
32. Gallagher SJ, Marshall JS, Hoskin DW. Human mast cells induce caspaseindependent DNA fragmentation in leukemic T cells. Oncol Rep 2003; 10:1019-1023.
33. den Dekker WK,Tempel D,Bot I,Biessen EA,Joosten LA,Netea MG,et al. Mast cells induce vascular smooth muscle cell apoptosis via a toll-like receptor 4 activation pathway Arterioscler Thromb Vasc Biol 2012 32 1960-1969.
34. Ebihara N, Funaki T, Murakami A, Takai S, Miyazaki M. Mast cell chymase decreases the barrier function and inhibits the migration of corneal epithelial cells. Curr Eye Res 2005; 30:1061-1069.
35. Whitaker-Menezes D, Schechter NM, Murphy GF. Serine proteinases are regionally segregated within mast cell granules. Lab Invest 1995; 72:34-41.
36. Goldstein SM, Leong J, Schwartz LB, Cooke D. Protease composition of exocytosed human skin mast cell protease-proteoglycan complexes. Tryptase resides in a complex distinct from chymase and carboxypeptidase. J Immun ol 1992; 148:2475-2482.
37. Kivinen PK, Nilsson G, Naukkarinen A, Harvima IT. Mast cell survival and apoptosis in organ-cultured human skin. Exp Dermatol 2003; 12:53-60.
38. Kankkunen JP, Harvima IT, Naukkarinen A. Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int J Cancer 1997; 72:385-388.
39. Ekoff M, Lyberg K, Krajewska M, Arvidsson M, Rak S, Reed JC, et al. Antiapoptotic BFL-1 is the major effector in activation-induced human mast cell survival. PLoS One 2012; 7:e39117.
40. Bolton LL, Montagna W. Mast cells in human ulcers. Am J Dermatopathol 1993; 15:133-138.
41. Green R, Cordero A, Winkelmann RK. Epidermal mast cells. Arch Dermatol 1977; 113:166-169.
42. Ar tuc M, Guhl S, Babina M, Unger T, Steckelings UM, Zuberbier T. Mast cellderived TNF-Alpha and histamine modify IL-6 and IL-8 expression and release from cutaneous tumor cells. Exp Dermatol 2011; 20:1020-1022.
43. Oldford SA, Haidl ID, Howatt MA, Leiva CA, Johnston B, Marshall JS. A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J Immunol 2010; 185 :7067-7076.
44. Harvima IT, Karkola K, Harvima RJ, Naukkarinen A, Neittaanmäki H, Horsmanheimo M, Fräki JE. Biochemical and histochemical evaluation of tryptase in various human tissues. Arch D ermatol Res 1989; 281:231-237.
45. Byrne SN, Limó n-Flores AY, Ullrich SE. Mast cell migration from the skin to the draining lymph nodes upon ultraviolet irradiation represents a key step in the induction o f immune suppression. J Immunol 2008; 180:4648-4655.
46. Wang HW, Tedla N, Lloyd AR, Wakefield D, McNeil PH. Mast cell activation and migration to lymph nodes during induction of an immune res ponse in mice. J Clin Invest 1998; 102:1617-1626.
47. Bond G, Nowocin A, Sacks SH, Wong W. Kinetics of mast cell migration during transplantation tolerance. Transpl Immunol 2015; 32:40-45.